Consequently, the first human clinical trials of dasatinib plus quercetin (D+Q) treatment for patients with idiopathic pulmonary fibrosis (IPF) and diabetic kidney disease (DKD) showed preliminary evidence of improved physical function measures, decreased adipose tissue senescent cell burden, and decreased circulating SASP factors like IL-1α and IL-6 [50,97]. This evidence concerns the gene IL6 and idiopathic pulmonary fibrosis.